Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Biostage, Inc. (OTC: BSTG).

Full DD Report for BSTG

Recent News from (OTC: BSTG)

Biostage Reports 2017 Financial Results
HOLLISTON, Mass. , April 2, 2018 /PRNewswire/ --  Biostage, Inc. (OTCQB : BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announc...
Source: PR Newswire
Date: April, 02 2018 08:00
Biostage Names Distinguished Children's Hospital Executive James Shmerling to its Board of Directors
HOLLISTON, Mass. , March 29, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it has appointed James Shmerling , DHA, F...
Source: PR Newswire
Date: March, 29 2018 16:10
Biostage awarded SBIR Fast-Track grant to develop Cellspan(TM) Esophageal Implant (CEI) as a novel treatment for esophageal atresia in pediatric patients
HOLLISTON, Mass. , March 29, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has been awarded a Fast-Track Small Business...
Source: PR Newswire
Date: March, 29 2018 08:00
Biostage preclinical study results published in new report
Biostage (NASDAQ: BSTG ) announces pre-clinical large-animal study results for its Cellspan esophageal implants. More news on: Biostage, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 13 2018 08:41
Biostage Preclinical Study Results Published in New Report
HOLLISTON, Mass. , March 13, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the publication of pre-clinical large-animal study results for its Ce...
Source: PR Newswire
Date: March, 13 2018 07:00
Biostage Closes $1 Million Private Placement
HOLLISTON, Mass. , Feb. 20, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the previously disclosed Securities Purchase Agreement with Jinhui Li...
Source: PR Newswire
Date: February, 20 2018 07:00
Biostage's (BSTG) Business Update Call - Slideshow
The following slide deck was published by Biostage, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: February, 14 2018 14:29
Biostage Appoints to its Scientific Advisory Board Charles S. Cox, Jr., MD
HOLLISTON, Mass. , Feb. 12, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the appointment of Charles S. Cox, Jr. , MD, Children's...
Source: PR Newswire
Date: February, 12 2018 08:00
Stocks To Watch: Digging For Gems In The Shakeout
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Are you not entertained? The broad-based selling in equities in the U.S. and across...
Source: SeekingAlpha
Date: February, 10 2018 08:37
Biostage, Inc. Names Jason Chen Chairman of its Board of Directors
HOLLISTON, Mass. , Feb. 7, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it has appointed Jason Jing Chen , Senior Vice P...
Source: PR Newswire
Date: February, 07 2018 16:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-242.602.622.622.605,861
2018-04-232.602.602.602.60288
2018-04-222.602.602.602.60100
2018-04-212.602.602.602.60100
2018-04-202.602.602.602.60100

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-04-091,0002,19545.5581Short
2018-04-061,2004,86424.6711Cover
2018-04-04917,2641.2528Cover
2018-04-035,1009,59653.1471Short
2018-03-291,0003,04132.8839Cover

* Cover Mode

Short Analysis provided by Squeeze Report.


About Biostage, Inc. (OTC: BSTG)

Logo for Biostage, Inc. (OTC: BSTG)

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company s Cellframe technology combines the synthetic scaffold with tissue engineering and cell biology to create method of addressing organ damage. Its Cellframe technology stimulates the body s signaling pathways and natural healing process to regenerate and restore organ function. The company is developing organ implants as a platform of being used in the esophagus, trachea, and bronchi. Its implants are being advanced and tested in a preclinical collaborative study with Mayo Clinic. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March . Biostage, Inc. was founded in and is headquartered in Holliston, Massachusetts.

 

Contact Information

 

 

Current Management

  • James McGorry / CEO
    • Mr. McGorry has served as our Chief Executive Officer CEO since July , . He has served as a Member of our Board of Directors since February . Mr. McGorry has more than years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. Prior to becoming CEO at Biostage, Mr. McGorry most recently served as Executive Vice President and General Manager, Translational Oncology Solutions for Champions Oncology and previously was Executive Vice President of Commercial Operations at Accellent. During a year tenure at Genzyme, he held leadership positions across several therapeutic areas, including Bio Surgery, Cardiac Surgery, Oncology and Transplant. Mr. McGorry also was President of Clineffect Systems, an electronic medical records company. He began his life sciences career with Baxter Healthcare Corporation, where he spent years in positions of increasing responsibility. Mr. McGorry also served as an officer in the United States Army for six years, including commanding a special operations Green Beret SCUBA detachment. Mr. McGorry has an MBA with a concentration in healthcare from Duke University, Fuqua School of Business, and a B.S. in engineering from the United States Military Academy at West Point where he was the president of his class.
  • Thomas McNaughton / CFO
    • Tom McNaughton was the Chief Financial Officer of Harvard Bioscience from November until the Company s spinoff from Harvard Bioscience in November . From to , Mr. McNaughton was a consultant providing services primarily to an angelinvesting group and a silicon manufacturing startup. From to , Mr. McNaughton served as Vice President of Finance and Chief Financial Officer for Tivoli Audio, LLC, a venture capitalbacked global manufacturer of premium audio systems. Prior to joining Tivoli Audio, LLC, from to , Mr. McNaughton served in various managerial positions in the areas of financial reporting, treasury, investor relations, and acquisitions within Cabot Corporation, a global manufacturer of fine particulate products, and served from to as Finance Director, Chief Financial Officer of Cabot Supermetals, a million Cabot division that provides high purity tantalum and niobium products to the electronics and semiconductor industries. Mr. McNaughton practiced from to as a Certified Public Accountant in the audit services group of Deloitte amp Touche, LLP. Mr. McNaughton holds a BS in accounting and finance from Babson College.
  • Jake Burgess / Director, Fin.
  • Jason Jing Chen / Chairman
  • John Canepa / Independent Director, Audit Committee Member, Nominating Committee Member
    • Mr. Canepa has served as a member of our Board of Directors since August , . Mr. Canepa is Chief Financial Officer of Stemgent, Inc., a provider of stem cell related products and services and a leading global provider of high quality, well characterized human tissue and human tissuebased research solutions to drug discovery scientists through its whollyowned subsidiary, Asterand, Inc. From August , Mr. Canepa served as the President and Chief Executive Officer of PathoGenetix, Inc., a venture capital backed life science company focused on commercializing proprietary DNA optical mapping technology for pathogen detection and strain identification. From to , Mr. Canepa served as the Chief Financial Officer at Winphoria Networks. From to , Mr. Canepa was a Senior Audit Partner in Arthur Andersen s Boston Office Technology Practice with worldwide responsibility for Life Sciences Practice. Currently, Mr. Canepa is a member of the Board of Trustees at Mt. Auburn Hospital and a member of the Audit Committee at CareGroup. He received his M.Fin from Michigan State University and his B.A. in economics from Denison University.
  • James McGorry / Director
    • Mr. McGorry has served as our Chief Executive Officer CEO since July , . He has served as a Member of our Board of Directors since February . Mr. McGorry has more than years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. Prior to becoming CEO at Biostage, Mr. McGorry most recently served as Executive Vice President and General Manager, Translational Oncology Solutions for Champions Oncology and previously was Executive Vice President of Commercial Operations at Accellent. During a year tenure at Genzyme, he held leadership positions across several therapeutic areas, including Bio Surgery, Cardiac Surgery, Oncology and Transplant. Mr. McGorry also was President of Clineffect Systems, an electronic medical records company. He began his life sciences career with Baxter Healthcare Corporation, where he spent years in positions of increasing responsibility. Mr. McGorry also served as an officer in the United States Army for six years, including commanding a special operations Green Beret SCUBA detachment. Mr. McGorry has an MBA with a concentration in healthcare from Duke University, Fuqua School of Business, and a B.S. in engineering from the United States Military Academy at West Point where he was the president of his class.
  • Blaine McKee / Independent Director, Audit Committee Member
    • Blaine McKee has served as member of our Board of Directors since March , . He is a broadly skilled senior executive with over years leadership experience in global biotechnology business development. Dr. McKee joined Shire in to lead its business development function. He was previously EVP and Chief Business Officer at Biomedical, following years at Genzyme Corporation, where he served as SVP of Strategic Development, leading global business development for the Organ Transplant, Oncology and Multiple Sclerosis business units. Dr. McKee contributed materially to the transformation of the oncology business at Genzyme from an earlystage research operation to a competitive and sustainable oncology and solid organ transplantation franchise, with global revenues of approximately M in . Dr. McKee is also on the boards of ArmaGen, OrbiMed Israel, and the New York Pharma Forum. He received his Bachelor of Science degree from Colorado State University, his PhD from the Massachusetts Institute of Technology, and his MBA from the MIT Sloan School of Management.
  • Thomas Robinson / Compensation Committee Member, Nominating Committee Member
    • Mr. Robinson has served as a member of our Board of Directors since December , . Since September , Mr. Robinson has served as a partner with RobinsonButler, an executive search firm. In , Mr. Robinson served as managing director at Russell Reynolds Associates. From to , Mr. Robinson served as managing partner of the North American medical technology practice, which includes the medical device, hospital supply/distribution and medical software areas, of Spencer Stuart, Inc., a global executive search firm. From to , Mr. Robinson was a member of Spencer Stuarts board services practice, which assists corporations to identify and recruit outside directors. From to , Mr. Robinson headed Spencer Stuarts North American biotechnology specialty practice. From to , Mr. Robinson served as president of the emerging markets business at Boston Scientific Corporation, a global medical devices manufacturer. From to , Mr. Robinson also served as president and chief operating officer of Brunswick Biomedical, a cardiology medical device company. Mr. Robinson currently serves on the Board of Directors of Cynosure, Inc. He received his M.B.A. from Harvard Business School and his B.A. in mathematics and economics from Brown University.

Current Share Structure

  • Market Cap: $9,150,141 - 03/20/2018
  • Authorized: 120,000,000 - 03/19/2018
  • Issue and Outstanding: 2,859,419 - 03/19/2018

 


Recent Filings from (OTC: BSTG)

Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 13 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 06 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 30 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: February, 27 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: February, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018

 

 


Daily Technical Chart for (OTC: BSTG)

Daily Technical Chart for (OTC: BSTG)


Stay tuned for daily updates and more on (OTC: BSTG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BSTG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BSTG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BSTG and does not buy, sell, or trade any shares of BSTG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us